MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim

Cell Biology International

Volumn 38, Issue 4, 2014, Pages 435-443

  Lv, Xiao Bin ^a   Zhang, Xing ^b   Deng, Lan ^b   Jiang, Ling ^b   Meng, Wei ^b   Lu, Zhigang ^b   Wang, Xiuju ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AP1; AZD6244; Bim; Lymphoma; MEK1 2; MiR 92a

Indexed keywords

BIM PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 92A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SELUMETINIB; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIM GENE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA CELL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

AP1; AZD6244; BIM; LYMPHOMA; MEK1/2; MIR-92A;

3' UNTRANSLATED REGIONS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; BENZIMIDAZOLES; CELL LINE; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; HEK293 CELLS; HUMANS; LYMPHOMA; MEMBRANE PROTEINS; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84895856538     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10225     Document Type: Article

References (36)

1. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, Gores GJ (2007) Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 282: 27141-54.
2. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-66.
3. Catalanotti F, Solit DB, PulitzerMP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19: 2257-64.
4. Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG (2011) Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br J Haematol 152: 401-12.
5. Courcelles M, Fremin C, Voisin L, Lemieux S, Meloche S, Thibault P (2013) Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol Syst Biol 9: 669.
6. Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, Oyen WJ (2012) (18)F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. World J NuclMed 11: 65-9.
7. Di Leva G, Croce CM (2013) The Role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 3: 153.
8. Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-7.
9. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM (2013) Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14: 134-40.
10. KarinM, Liu Z, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9: 240-6.
11. Kawabata T, Tanimura S, Asai K, Kawasaki R, Matsumaru Y, Kohno M (2012) Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor. J Biol Chem 287: 10289-300.
12. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA (2011) In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras (G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 10: 1440-9.
13. Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38: 200-11.
14. Lin S, Hoffmann K, Xiao Z, Jin N, Galli U, Mohr E, Büchler MW, Schemmer P (2013) MEKinhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int 13: 3.
15. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, Sun XF (2013) Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 34: 2175-81.
16. Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, Wu M, Liang Y, Liu P, Tang J, Lu WH, Feng QS, Chen LZ, Qian CN, Bei JX, Kang T, Zeng YX (2012) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11: 2495-506.
17. Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, Song E, Yu F (2011) miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer 30: 821-30.
18. Lv XB, Lian GY, Wang HR, Song E, Yao H, Wang MH (2013) Long noncoding RNA HOTAIR is a prognostic marker for esophageal squamous cell carcinoma progression and survival. PLoS ONE 8: e63516.
19. Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT (2013) Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. Invest New Drugs 31: 30-8.
20. Martin-Sanchez E, Rodriguez-Pinilla SM, Sanchez-Beato M, Lombardia L, Dominguez-Gonzalez B, Romero D, Odqvist L, García-Sanz P, Wozniak MB, Kurz G, Blanco-Aparicio C, Mollejo M, Alves FJ, Menárguez J, González-Palacios F, Rodríguez-Peralto JL, Ortiz-Romero PL, García JF, Bischoff JR, Piris MA (2013) Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica 98: 57-64.
21. Mebratu Y, Tesfaigzi Y (2009) How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8: 1168-75.
22. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RASmutant colorectal carcinomas. Clin Cancer Res 18: 2515-25.
23. Min D, Lv XB, Wang X, Zhang B, Meng W, Yu F, Hu H (2013) Downregulation of miR-302c and miR-520c by 1,25 (OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer 109: 723-30.
24. Miyagaki T, Sugaya M, Murakami T, Asano Y, Tada Y, Kadono T, Sato S (2011) CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. Cancer Res 71: 2056-65.
25. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, Gutkind JS (2005) Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280: 35081-4.
26. O'Donnell A, Yang SH, Sharrocks AD (2008) MAP kinasemediated c-fos regulation relies on a histone acetylation relay switch. Mol Cell 29: 780-5.
27. Patel SP, Kim KB (2012) Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21: 531-9.
28. Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM (2012) MiR-494 is regulated by ERK1/2, modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 109: 16570-5.
29. Roskoski R, Jr. (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66: 105-43.
30. Ruvkun G (2006) Clarifications on miRNA and cancer. Science 311: 36-7.
31. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110: 1656-63.
32. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M (2011) miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 102: 2264-71.
33. Wang J, Liu L, Xie L, Xiang G, Zhou Y (2013) Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation. Int J Mol Med 31: 59-66.
34. Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, Ong RW, Huynh H (2008) Colorectal cancer cells with the BRAF (V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27: 7150-61.
35. Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H (2012) Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. Int J Oncol 41: 712-20.
36. Zhao B, Zhu Y, Cui K, Gao J, Yu F, Chen L, Li S (2013) Expression and significance of PTEN and miR-92 in hepatocellular carcinoma. Mol Med Rep 7: 1413-6.